[ad_1] Results from the 8,179-subject REDUCE-IT study evaluation Amarin's (NASDAQ: AMRN) Vascepa (icosapent ethyl) in statin-treated adults with elevated cardiovascular (CV) risk showed a significant treatment effect. The data were presented at …
Read More »Amarin's Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCED-study – Amarin Corporation PLC (NASDAQ: AMRN)
